Heather Anong Wasserman

US Patent:

20120014950, Jan 19, 2012

Filed:

Aug 24, 2011

Appl. No.:

13/217023

Inventors:

Thi-Sau Migone - Gaithersburg MD, US
Chih-Hung Lo - Rockville MD, US
Luke Oh - Potomac MD, US
Heather Wasserman - Gaithersburg MD, US
Madhav Devalaraja - Rockville MD, US
Matthew J. Bernett - Monrovia CA, US

Assignee:

Xencor, Inc. - Monrovia CA
Human Genome Sciences, Inc. - Rockville MD

International Classification:

A61K 39/395
A61P 29/00
A61P 37/02
A61P 19/10
A61P 1/00
A61P 25/00
A61P 37/08
A61P 35/00
C07K 16/00
A61P 19/02

US Classification:

4241331, 5303873

Abstract:

The present invention relates to antibodies, antibody fragments, and related molecules that specifically bind to DR3 receptors. Such antibodies have uses, for example, in the prevention, detection, diagnosis, treatment or amelioration of a disease or disorder, especially inflammatory and autoimmune diseases and other immune system disorders, such as Crohn's disease, colitis, Inflammatory Bowel Disease, arthritis, asthma, Multiple Sclerosis, atherosclerosis, and allergic disorders. The invention also relates to nucleic acid molecules encoding anti-DR3 receptor antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially inflammatory or autoimmune disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to DR3 receptor.

US Patent:

20110311548, Dec 22, 2011

Filed:

Jun 17, 2011

Appl. No.:

13/163593

Inventors:

Heather Wasserman - Gaithersburg MD, US
Timothy L. Carlson - Silver Spring MD, US
Thi-Sau Migone - Gaithersburg MD, US
Madhav Devalaraja - Rockville MD, US

Assignee:

HUMAN GENOME SCIENCES, INC. - Rockville MD

International Classification:

A61K 39/395
A61P 11/06
A61P 11/00
A61K 38/16
A61K 39/35

US Classification:

4241451, 4241581, 514 17, 4242751

Abstract:

The invention relates to methods of preventing, treating, and ameliorating asthma, allergen-induced respiratory symptoms, and/or an allergic or inflammatory condition of the lung or respiratory system in a patient by administering B Lymphocyte Stimulator antagonists. In addition, the invention provides a method of reducing total serum IgE levels in a patient suffering from asthma, and/or an allergic or inflammatory condition of the lung or respiratory system by administering B Lymphocyte Stimulator antagonists. The invention further provides a method of treating, preventing or ameliorating an allergen-induced airway hyper responsiveness or increase in mucus-containing cells and/or mucus accumulation or production in the airway epithelium of a patient by administering B Lymphocyte Stimulator antagonist.